http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임정규,홍사악,박찬웅,김명석,서유헌,신상구,김용식,김혜원,이정수,장기철,이상국,장우현,김익상,Lim J.K.,Hong S.A.,Park C.W.,Kim M.S.,Suh Y.H.,Shin S.G.,Kim Y.S.,Kim H.W.,Lee J.S.,Chang K.C.,Lee S.K.,Chang K.C.,Kim I.S. 대한약리학회 1980 대한약리학잡지 Vol.16 No.2
The pharmacological and microbiological studies of Cefoperazone (T-1551, Toyama Chemical Co., Japan) were conducted in vitro and in vivo. The studies included stability and physicochemical characteristics, antimicrobial activity, animal and human pharmacokinetics, animal pharmacodynamics and safety evaluation of Cefoperazone sodium for injection. 1) Stability and physicochemical characteristics. Sodium salt of cefoperazone for injection had a general appearance of white crystalline powder which contained 0.5% water, and of which melting point was $187.2^{\circ}C$. The pH's of 10% and 25% aqueous solutions were 5.03 ana 5.16 at $25^{\circ}C$. The preparations of cefoperazone did not contain any pyrogenic substances and did not liberate histamine in cats. The drug was highly compatible with common infusion solutions including 5% Dextrose solution and no significant potency decrease was observed in 5 hours after mixing. Powdered cefoperazone sodium contained in hermetically sealed and ligt-shielded container was highly stable at $4^circ}C{\sim}37^{\circ}C$ for 12 weeks. When stored at $4^{\circ}C$ the potency was retained almost completely for up to one year. 2) Antimicrobial activity against clinical isolates. Among the 230 clinical isolates included, Salmonella typhi was the most susceptible to cefoperazone, with 100% inhibition at MIC of ${\leq}0.5{\mu}g/ml$. Cefoperazone was also highly active against Streptococcus pyogenes(group A), Kletsiella pneumoniae, Staphylococcus aureus and Shigella flexneri, with 100% inhibition at $16{\mu}g/ml$ or less. More than 80% of Escherichia coli, Enterobacter aerogenes and Salmonella paratyphi was inhibited at ${\leq}16{\mu}/ml$, while Enterobacter cloaceae, Serratia marcescens and Pseudomonas aerogenosa were somewhat less sensitive to cefoperagone, with inhibitions of 60%, 55% and 35% respectively at the same MIC. 3) Animal pharmacokinetics Serum concentration, organ distritution and excretion of cefoperazone in rats were observed after single intramuscular injections at doses of 20 mg/kg and 50 mg/kg. The extent of protein binding to human plasma protein was also measured in vitro br equilibrium dialysis method. The mean Peak serum concentrations of $7.4{\mu}g/ml$ and $16.4{\mu}/ml$ were obtained at 30 min. after administration of cefoperazone at doses of 20 mg/kg and 50 mg/kg respectively. The tissue concentrations of cefoperazone measured at 30 and 60 min. were highest in kidney. And the concentrations of the drug in kidney, liver and small intestine were much higher than in blood. Urinary and fecal excretion over 24 hours after injetcion ranged form 12.5% to 15.0% in urine and from 19.6% to 25.0% in feces, indicating that the gastrointestinal system is more important than renal system for the excretion of cefoperazone. The extent of binding to human plasma protein measured by equilibrium dialysis was $76.3%{\sim}76.9%$, which was somewhat lower than the others utilizing centrifugal ultrafiltration method. 4) Animal pharmacodynamics Central nervous system : Effects of cefoperazone on the spontaneous movement and general behavioral patterns of rats, the pentobarbital sleeping time in mice and the body temperature in rabbits were observed. Single intraperitoneal injections at doses of $500{\sim}2,000mg/kg$ in rats did not affect the spontaneous movement ana the general behavioral patterns of the animal. Doses of $125{\sim}500mg/kg$ of cefoperazone injected intraperitonealy in mice neither increased nor decreased the pentobarbital-induced sleeping time. In rabbits the normal body temperature was maintained following the single intravenous injections of $125{\sim}2,000mg/kg$ dose. Respiratory and circulatory system: Respiration rate, blood pressure, heart rate and ECG of anesthetized rabbits were monitored for 3 hours following single intravenous inje
이선기(S. K. Lee),이상국(S. G. Lee),박성근(S. K. Park),노영진(Y. J. Rho) 한국동력기계공학회 2008 한국동력기계공학회 학술대회 논문집 Vol.2008 No.11
The CANDU type reactors require on power refuelling by the two remotely controlled fuelling machines. The refuelling operation is carried out along the coolant direction by the drag force of fuel bundles for most channels. However, for about 30% of channels the coolant flow is not sufficiently high enough to carry fuel bundles to the downstream. Therefore, a device, FARE (Flow Assist Ram Extension) device, is used to create an additional drag force to push the fuel bundles along the coolant flow. The FARE device has been causing the channel flow low phenomena of channels due to more than excessive blockage of coolant flow. The flow rate change for the channels is monitored on line for the coolant flow blockage of the channels. This has initiated the investigation of the FAKE device behavior and the cause and remedy for the problem. The analysis revealed that the channel flow low occurs as the insertion of the FARE device into the active core flow and disappears as the removal of the FARE device from it. In order to eliminate the channel flow low phenomena, flow resistance by the FARE device should be reduced. The analysis has revealed that a too much relaxation of flow resistance would make the FARE device unable to push the fuel bundle string, and a too little relaxation would make the FARE device unable to eliminate the channel flow low phenomena. Suggested design changes include more flow holes in the tube.